Posted by Michael Wonder on 26 Sep 2016
As Clinton-Trump debate looms, it's drug prices, not Obamacare, taking stage
25 September 2016 - When Hillary Clinton and Donald Trump debate on Monday night, the pharmaceutical industry and its series of missteps on pricing everything from heart medications to EpiPens could enter the presidential crossfire.
Both Clinton and Trump have already weighed in on pharmaceutical industry price increases with different remedies on how to put a lid on them. And analysts see drug makers being their target in upcoming debates, particularly after Republicans and Democrats in Congress grilled Mylan CEO Heather Bresch over the 400% price hike for the life-saving EpiPen device for allergy sufferers.
